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Phenotypic  resistance  analysis  is  an indispensable  method  for  determination  of  HIV-1 resistance  and
cross-resistance  to novel  drug compounds.  Since  integrase  inhibitors  are  essential  components  of recent
antiretroviral  combination  therapies,  phenotypic  resistance  data,  in  conjunction  with  the correspond-
ing  genotypes,  are  needed  for improving  rules-based  and  data-driven  tools  for  resistance  prediction,
such  as  HIV-Grade  and geno2pheno[integrase]. For  generation  of phenotypic  resistance  data  to recent  inte-
grase  inhibitors,  a recombinant  phenotypic  integrase  susceptibility  assay  was  established.  For  validation
purposes,  the  phenotypic  resistance  to  raltegravir,  elvitegravir  and  dolutegravir  of nine  subtype-B  virus
strains, isolated  from  integrase  inhibitor-naïve  and  raltegravir-treated  patients  was determined.  Geno-
typic  resistance  analysis  identiﬁed  four  virus strains  harbouring  RAL  resistance-associated  mutations.
Phenotypic  resistance  analysis  was  performed  as  follows.  The  HIV-1  integrase  genes  were  cloned  into
a modiﬁed  pNL4-3  vector  and  transfected  into  293T  cells  for the  generation  of recombinant  virus.  The
integrase-inhibitor  susceptibility  of  the  recombinant  viruses  was  determined  via an  indicator  cell  line.
While  raltegravir  resistance  proﬁles  presented  a high  cross-resistance  to  elvitegravir,  dolutegravir  main-
tained  in-vitro  activity  in  spite  of the Y143R  and  N155H  mutations,  conﬁrming  the  strong  activity  of
dolutegravir  against  raltegravir-resistant  viruses.  Solely  a Q148H  + G140S  variant  presented  reduced
susceptibility  to  dolutegravir.  In conclusion,  our  phenotypic  susceptibility  assay  permits  resistance  anal-
ysis of the integrase  gene  of  patient-derived  viruses  for  integrase  inhibitors  by replication-competent
recombinants.  Thus,  this  assay  can be used  to analyze  phenotypic  drug  resistance  of  integrase  inhibitors
in  vitro.  It provides  the  possibility  to determine  the  impact  of  newly  appearing  mutational  patterns  to
drug  resistance  of  recent  integrase  inhibitors.
© 2016  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND. Introduction
Since HIV-1 requires lifelong treatment, it is highly desirable
hat antiretroviral drugs have the following characteristics: (1)
igh potency against viral replication, (2) good long-term toler-
bility, and (3) a high barrier to resistance. These characteristics
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166-0934/© 2016 The Authors. Published by Elsevier B.V. This is an open access article 
/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
are displayed by HIV-1 integrase inhibitors (INIs), the most recent
class of antiretroviral drugs. Antiretroviral activity of INIs arises
from their ability to inhibit the strand-transfer activity of HIV-1
integrase (IN), thus preventing the integration of proviral DNA into
the host genome, which is an indispensable step in viral replica-
tion (Hazuda et al., 2000). Raltegravir (RAL), elvitegravir (EVG), and
dolutegravir (DTG) are the currently available INIs.
In 2007, the ﬁrst INI, RAL, was approved for the treatment
of patients infected with HIV-1, followed by EVG in 2012. These
ﬁrst-generation INIs are highly efﬁcacious in the treatment of
HIV-1-infected subjects, but suffer from a low barrier to resis-
tance, resulting in rapid emergence of resistance mutations (Geretti
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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t al., 2012; Grobler and Hazuda, 2014; Quashie et al., 2013).
esistance to RAL is induced by three clearly identiﬁed major
esistance pathways, involving primary/major mutations at the IN
esidues Y143, Q148, and N155, respectively. Since primary/major
esistance mutations for EVG include T66I, E92Q, Q148H/R/K, and
155H, RAL and EVG present broad cross resistance (Blanco et al.,
011; Garrido et al., 2012; Geretti et al., 2012; McColl et al., 2007;
ichtig et al., 2009). In contrast, pathways leading to primary resis-
ance to DTG have not yet been identiﬁed, but likely involve the
ccumulation of multiple mutations (Kobayashi et al., 2011).
DTG is a second-generation INI that was approved in 2014
or use in treatment-naïve and treatment-experienced patients,
ncluding INI-experienced patients. Compared to RAL and EVG,
TG has a higher resistance barrier since resistance is only slowly
elected in vitro and has not emerged in studies of therapy-naïve
atients, up to date (Llibre et al., 2015; Rafﬁ et al., 2013; Wainberg
t al., 2013; White et al., 2014). Antiviral activity of DTG in spite
f resistance to RAL and EVG has been shown in vitro, with only
imited cross resistance to RAL and EVG resistant viruses (Seki
t al., 2015; Underwood et al., 2012; Van Wesenbeeck et al., 2011).
his has been conﬁrmed in clinical studies with patients harbour-
ng RAL-resistant HIV-1 strains (Arribas et al., 2010; Eron et al.,
010). Nevertheless, decreased susceptibility to DTG is shown by
solates with a major INI-resistance mutation at residue Q148 and
dditional minor INI-resistance mutations (Abram et al., 2013;
nderwood et al., 2012). DTG is highly efﬁcacious in treatment-
aïve and treatment-experienced patients, regardless of previous
herapies. In the clinic, this has led to an increase in INI use in ﬁrst
nd second-line therapies. Some mutations selected in vitro and
n vivo are potentially involved in resistance to DTG, e.g. muta-
ions at residues G118, F121, E138, S153, and R263 (Kobayashi
t al., 2011; Quashie et al., 2012). However, their impact on DTG
esistance and cross-resistance to other INIs remains unclear.
Resistance development is characterized by the appearance
f a major resistance mutation followed by the accumulation
f resistance mutations that further increase drug resistance or
estore viral replication capacity. Thus, it is important to inves-
igate the complete mutation patterns of HIV-1 IN and not only
ingle resistance mutations. We  therefore developed a phenotypic
N susceptibility assay that allows for assessment of resistance and
ross-resistance to INIs in patient-derived viruses.
We will use our newly developed phenotypic resistance assay
or generating genotype-phenotype pairs, which will in turn be
sed for analysing INI resistance in different HIV-1 strains. Specif-
cally, we want to produce genotype-phenotype pairs that are
ndependent of controlled clinical studies and use them for char-
cterization of INI-resistance mutations that are associated with
herapy failure. Furthermore, this data will be used for improving
he interpretation of HIV-1 genotypes with respect to resistance
o INIs. Genotype-phenotype pairs can be used for identifying
omplex resistance patterns and for the improvement of the bioin-
ormatics tool geno2pheno[integrase], which offers freely available
henotype-based INI-resistance predictions. geno2pheno[integrase]
ersion 2.0 was trained on 285 RAL- and 228 EVG genotype-
henotype pairs from the Stanford HIV Drug Resistance Database
http://hivdb.stanford.edu). These genotype-phenotype pairs orig-
nate from controlled clinical studies and were predominantly
enerated with commercial phenotypic assays.
. Materials and methods
.1. Materials.1.1. Viral samples
Subtype-B viral samples were obtained from patients of the
ESINA cohort (BMG: IIA5-2013-2514AUK375). Analysis of INIl Methods 238 (2016) 29–37
resistance was  performed on nine plasma samples harbouring
viruses with different genotypic integrase proﬁles. Five sam-
ples were obtained of patients without INI treatment history
harbouring viruses presenting genotypically none of the known
INI resistance mutations (#1-5) as negative control. For phe-
notypic determination of INI resistance, four plasma samples
of patients after RAL-therapy failure harbouring viruses with
described RAL resistance mutations (#6-9) were analysed. Subtyp-
ing was  performed with the COMET HIV-1 subtyping tool, version
0.2 (http://comet.retrovirology.lu/).
2.1.2. Integrase inhibitors
RAL was  kindly provided by Merck. EVG and DTG were pur-
chased from Selleckchem (pure substances).
2.2. Methods
We  performed genotypic and phenotypic INI-resistance analy-
ses on the IN gene region of nine patient-derived HIV-1 subtype-B
virus strains. For this purpose, we  considered RAL, EVG, and DTG.
The samples were selected according to their genotypic resistance
proﬁle.
2.2.1. Genotypic INI-resistance analysis
For the selection of convenient plasma samples for the vali-
dation of the phenotypic susceptibility assay for INIs, genotypic
resistance analysis of the integrase gene region was performed
as previously described (Sichtig et al., 2009). Mutations in each
IN sequence were determined by comparison to HXB2, an HIV-1
subtype-B reference strain. The prediction of genotypic resistance
of the viruses against RAL, and cross-resistance against EVG and
DTG and the scored INI resistance-associated mutations were
deﬁned according to published data (reviewed in (Blanco et al.,
2011; Quashie et al., 2013)) and the Stanford Drug Resistance
Database (http://hivdb.stanford.edu).
2.2.2. Vector design
We  cloned the HIV-1 IN region of each viral isolate into the
HIV-1 complete-genome vector pNL4-3 (GenBank accession no.
AF324493 constructed by (Adachi et al., 1986)). For this purpose,
the vector had to be modiﬁed to pNL4-3IN. The EcoRI restriction
site at nucleotide (nt) positions 5743–5748 and the NcoI site at nt
positions 10,565–10,570 were deleted. Furthermore, we inserted
an EcoRI site at nt positions 4171–4176 (pol gene) and an NcoI site
at nt position 5098–5103 (Fig. 1a). We  used site-directed muta-
genesis for inserting the EcoRI and the NcoI sites and for deleting
the EcoRI at nt positions 5743–5748 (see primers in Table 1), in
accordance with the manufacturer’s protocol (QuickChangeTM Site
Directed Mutagenesis Kit, Stratagene). For deleting the NcoI site at
nt postion 10565 in pNL4-3, we  digested the vector with the NcoI
enzyme, subsequently ﬁlling up the 5′-overlapping single-stranded
DNA via Klenow fragment and religating the vector. In addition to
deleting the Ncol site, this resulted in a 4 nt insertion (CATG).
2.2.3. IN ampliﬁcation and puriﬁcation
Viral RNA from 1000 l plasma was  isolated automatically using
the MagNA Pure Compact Nucleic Acid Isolation Kit I and the MagNA
PureTM Compact System (Roche Diagnostics), according to the man-
ufacturer’s instructions. cDNA of the RNA was generated using the
SuperScript III RT Kit (Invitrogen) with the primer 5220as (Table 1).
Ampliﬁcation of the integrase gene was  performed via nested PCR
with the HotStarTaq-Polymerase (Qiagen), according to the com-
pany’s protocol. The ﬁrst PCR was  performed with the outer primers
4140 s and 5220as and the second PCR was  performed with the
inner primers 4166MfeI and 5077PciI (Table 1). These primers are
E. Heger et al. / Journal of Virological Methods 238 (2016) 29–37 31
Fig. 1. (a) Schematic representation of the pNL4-3IN construct.
The EcoRI restriction site at position 5743–5748 and the NcoI restriction site at position 10565–10570 were deleted, while an EcoRI (4171–4175) and an NcoI (5098–5103)
restriction site ﬂanking the integrase gene were introduced. The nucleotide positions highlighted in bold were exchanged by site-directed mutagenesis. (b) Schematic
representation of the cloning of the ampliﬁed IN gene into pNL4-3IN to NL4-3lig IN. The IN PCR amplicons were ﬂanked with the recognition sites for MfeI and PciI, which
overhangs are compatible cohesive to the EcoRI and NcoI sites of pNL4-3IN allowing a ligation without produced amino acid exchanges. The nucleotides highlighted in
bold  present the restriction overhangs generated by the different enzymes.
Table 1
Oligonucleotides used for vector preparation, IN cloning and IN sequencing.
Primer Sequence 5′ → 3′ Position (NL4-3) Application
t5747a-s AAGCCATAATAAGAATACTGCAACAACTGCTGTTTATCCATTTC 5731 −−→ 5774 EcoRI-Deletion
t5747a-as GATAAACAGCAGTTGTTGCAGTATTCTTATTATGGCTTCCACTC 5725 ←− 5768 EcoRI-Deletion
g4176c-s GTACCAGCACACAAAGGAATTCGAGGAAATGAACAAG 4155 −−→ 4191 EcoRI-Insertion
g4176c-as CTTGTTCATTTCCTCGAATTCCTTTGTGTGCTGGTAC 4155 ←− 4191 EcoRI-Insertion
a5098c-s CAAGTAGACAGGATGAGGATTAACCCATGGAAAAGATTAGTAAAACA 5074 −−→ 5120 NcoI-Insertion
a5098c-as TGTTTTACTAATCTTTTCCATGGGTTAATCCTCATCCTGTCTACTTG 5120 ←− 5174 NcoI-Insertion
5′-INT ATTGGAGGAAATGAACAAGT 4173 −−→ 4192 PCR
3p31 ATCCTGTCTACYTGCCACACAA 5066 ←− 5087 PCR
4140s GTCTACCTGGCATGGGTACCAGCAC 4140 −−→ 4164 PCR
ﬂ
i
a
T
f
a5220as CCCTAGTGGGATGTGTACTTCTGA 
4166MfeI CAAAGCAATTGGAGGAAATGAACAAGT 
5077PciI CGTTACATGTTCTAATCCTCATCCTGTCTAC 
anked with restriction sites for MfeI and PciI which have compat-
ble cohesive ends to the restriction sites EcoRI and NcoI, allowing successful cloning of the integrase gene into pNL4-3IN (Fig. 1b).
hermal cycling of both PCRs consisted of an activation step at 95 ◦C
or 15 min. The ﬁrst PCR consisted of 35 cycles. Each cycle spent 30s
t 95 ◦C, 30s at 58 ◦C and 2 min  at 72 ◦C. The second PCR was  a touch-5197 ←− 5220 PCR
4166 −−→ 4192 PCR
5077 −−→ 5107 PCR
down PCR comprising 45 cycles of 30s at 95 ◦C, 45s at 65◦ down to
58 ◦C in 4 cycles and 3 min  at 72 ◦C. Both PCRs had a ﬁnal elongation
step for 10 min  at 72 ◦C.
The 911 bp PCR amplicons were puriﬁed (QIAquick PCR Puriﬁ-
cation Kit, Qiagen) and quantiﬁed.
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.2.4. Cloning strategy
In order to produce pNL4-3IN vectors for ligation with IN PCR-
roducts, the restriction sites of the modiﬁed pNL4-3 vector were
igested with the endonucleases EcoRI and NcoI for 6 h at 37 ◦C.
ubsequently, the NL4-3IN-fragment (13902 bp) was puriﬁed by
el extraction.
In order to enhance the ligation efﬁciency of IN PCR-products
IN-MfeI/PciI) and the pNL4-3IN vector, we used the pDrive
loning vector (Qiagen) in an intermediate step. Speciﬁcally, 100 ng
f the puriﬁed IN PCR product and 1 l of the pDrive cloning vector
ere ligated and transformed into competent JM109 cells. After
ultivation and plasmid preparation, the DNA clones were veri-
ed by restriction analysis and sequencing. The integrase genes of
he respective clones were cleaved using the framed endonucleases
feI and PciI and extracted with a gel. 20 ng of the extracted frag-
ents and 60 ng of pNL4-3IN (ratio 1:5) were used for the ligation
eaction (15 h at 15 ◦C). After transformation into JM109 cells, plas-
id  DNA was isolated and controlled by restriction analysis with
feI with expected fragment sizes of 1747, 3930, and 9151 bp. All
ositive clones were analysed by sequencing in order to verify the
utations. For the generation of a wildtype reference strain pNL4-
lig IN, the integrase gene of pNL4-3 was ampliﬁed and ligated
n into pNL4-3IN, using exactly the same procedure applied to
he patients’ virus variants. Note that neither the insertion nor the
eletion restriction sites changed the amino acid sequence of the
NL4-3lig IN after cloning, since compatible restriction sites were
sed for ligating the vector and the insert, thus restoring the original
mino acid sequence of the NL4-3 backbone (Fig. 1b).
.2.5. Cultivation of recombinant virus
For the generation of recombinant virus, the plasmid DNA
10 g), which contained the recombinant virus genome, was
ransfected into 293T cells (1.5 million cells per plate), using the
uperFect transfection reagent (Qiagen), in accordance with the
anufacturer’s protocol. Recombinant viral particles were gen-
rated by the transfected 293T cells and were harvested from
he supernatant two days after transfection. For this purpose, the
upernatant was centrifuged at 1500 rpm for 5 min, aliquoted and
tored at −80 ◦C. In order to generate high-titer infectious-virus
upernatants, 2 ml  of the 293T supernatants were used to infect
0 ml  CEMx174 cells (100.000 cells/mL) and cultured for 3–5 days
ntil a cytopathic effect (CPE) was visible. Supernatant aliquots
ere stored at −80 ◦C. The IN genotype of the cultivated viruses was
eriﬁed by sequencing analysis. Due to the differential replication
apacity of each recombinant strain, virus titers varied between
amples. For this reason, phenotypic susceptibility was  tested with
ample-speciﬁc supernatant volumes. These volumes were deter-
ined with a virus titration assay. Speciﬁcally, the indicator cell
ine CEMx174-SIV-SEAP (Means et al., 1997) was infected with 1, 5,
0, or 20 l of the virus stock as, described by Walter et al. (Walter
t al., 1999). In CEMx174-SIV-SEAP cells, HIV-1 Tat protein transac-
ivates the stably integrated SEAP reporter construct, which leads
o a strong increase in SEAP activity. This activity can be measured
n the supernatant using the Phospha-LightTM SEAP (Secreted Pla-
ental Alkaline Phosphatase) Reporter Gene Assay System (Applied
iosystems, Part Number T1015) three days after infection. Equiva-
ent supernatant volumes were determined by normalization with
espect to 20.000 relative light units (RLU). The equivalent super-
atant volume for each sample was used as the input for the
usceptibility assay.
.2.6. Susceptibility assay
Walter et al., 1999; describes a procedure for phenotypic resis-
ance analysis (Fig. 2). (Walter et al., 1999). Since this procedure had
nly been established for NRTIs, NNRTIs, and PIs, it was  adapted in
rder to perform INI resistance and cross resistance analysis of thel Methods 238 (2016) 29–37
recombinant clones, as follows. The INIs were used in a serial dilu-
tion with a dilution factor of 3. The concentrations of RAL, EVG, and
DTG ranged between 0 and 10 M,  0–3 M,  and 0–0.1 M,  respec-
tively. Equivalent supernatant volumes, as calculated by the virus
titration assay, were used to determine the viral susceptibility to
INIs in a 96-well format. For this purpose, CEMx174-SIV-SEAP cells
were infected in triplicate with the calculated 20.000 RLU dose of
the recombinant virus clones in the presence of the respective drug
concentrations. For standardisation, the susceptibility of the refer-
ence strain NL4-3lig IN to the different INIs was  determined on
every 96-well plate, additionally.
The replicative capacity of the recombinant viruses was deter-
mined three days after infection by measuring the SEAP activity
of the virus cultures and of the reference virus. Using the decline
of RLUs in the serial drug dilutions, the mean 50% inhibitory drug
concentration (IC50) was determined. The fold change (FC) values
were calculated by dividing the determined mean IC50 value of a
recombinant virus clone by that for the reference strain NL4-3lig IN.
2.2.7. Analysis
The correlation of the determined FC values mea-
sured in the established phenotypic susceptibility assay
and the predicted FC values by geno2pheno[integrase]
was calculated with Pearson’s correlation coefﬁcient (R)
(http://www.socscistatistics.com/tests/pearson/Default2.aspx).
3. Results
3.1. Genotypic resistance analysis
For evaluating the phenotypic resistance test for INIs, nine dif-
ferent patient-derived subtype-B virus strains with and without
RAL resistance-associated mutations were analysed. The selection
of the viruses was based on the integrase genotypes which were
analysed in the context of routine diagnostics of resistance testing.
Three of the viruses isolated from RAL-experienced patients har-
boured mutations conferring resistance to RAL in vivo, including
the primary mutation N155H combined with the secondary muta-
tion G163R (#7), the primary mutation Y143R associated with the
secondary mutations T97A and E138K (#8), and the primary muta-
tion Q148H with the secondary mutation G140S (#9). The virus
strain #6 presented only the secondary RAL-resistance mutation
V151I (Table 2). The genotyped viruses #1-5 presented none of the
described RAL-resistance mutations.
3.2. Phenotypic resistance analysis
After characterization of the IN genotypes, the integrase region
of the selected viruses was  ampliﬁed and cloned into the modiﬁed
pNL4-3 vector (pNL4-3IN) for generating recombinant viruses in
cell culture. Sample-speciﬁc volumes of virus supernatants (20.000
RLU dose determined via virus titration assay) were used for the
measurement of virus replication under drug exposure by means
of the susceptibility assay. A schematic overview of the IN suscep-
tibility assay is pictured in Fig. 2.
The determined IC50 values of the ﬁve HIV-1 clones without
genotypic resistance to all INIs (#1-5) were predominately com-
parable to those of the reference strain NL4-3lig IN, with the
exception of clone #2 (Table 3, Fig. 3). This wildtype strain (#2)
presented unexpected susceptibility results to EVG and DTG. The
mean IC50-value for EVG was 23.78 nM (range 3.32–4.40) and for
DTG 2.89 nM (range 1.41–1.94), with a mean calculated fold change
(FC) of 3.78 and 1.59, respectively. As these increased fold changes
are most probably a result of a reduced replication capacity of the
recombinant virus and not of an initial reduced susceptibility to the
drugs, clone #2 was  excluded of the analysis. The mean IC50-values
E. Heger et al. / Journal of Virological Methods 238 (2016) 29–37 33
Fig. 2. Schematic representation of the phenotypic IN resistance assay.
IN  RT-PCR products were cloned into a modiﬁed IN-deleted pNL4-3 backbone. Recombinant plasmid DNA was transfected and viruses were cultivated. Finally, viral replication
was  measured with a reporter gene assay.
Table 2
Substitutions of RAL-treated patients analysed for phenotypic INI-susceptibility.
Sample Substitutions (relative to the reference strain HXB2)
#1–4773 D10E, K14R, R20 K, A23 V, V31I, V72I, G123S, A124T, R127 K, T206S, N232D, L234G, N254Q
#2–4867 D3G, D10E, E11D, R20 K, V31I, M50I, L101I, T112I, G123S, A124T, R127 K, K136Q, G163E, G193E,S230N, N232D
#3–7459 D10E, K14R, R20 K, V31I, P90S, S119G, T122I, G123S, A124T, T125A, R127 K, K156N, V201I, T206S, D229N, S230N, N232E, S283G
#4–7480 D10E, K14R, V72I, A91E, L101I, T112A, S119R, G123S, A124N, R127 K, K156N, S195C, N232D, M275L
#5–307 D10E, E11D, V31I, V72I, L101I, K111T, S119P, G123S, A124T, R127 K, F181Y, K219N, N222 K, N232D
#6–4939 D10E, I113 V, G123S, A124T, R127 K, V151I, N232D, L234V
#7–4833 D10E, S17N, V31I, V72I, V75A, T112 V, G123S, A124N, T125A, V126L, R127 K, N155H, G163R, S230N, N232D, D256E, D278G
#8–5150 D10E, S17N, M22I, A23 V, L28I, L45 V, L68 V, V72I, T97A, L101I, S119T,G123S, A124T, R127 K, E138 K, Y143R,  N232D, D256E
#9–6834 D10E, S17N, L28I, S39C, L45 V, V72I, I113L, G123S, A124N, T125A, R127 K, G140S, Q148H, G163Q, V201I, N232D, V259I, K266R, S283G
M
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(utations highlighted bold: Primary RAL resistance-associated mutations.
utations underlined: Secondary RAL resistance-associated mutations.
or the remaining four strains without deﬁned RAL resistance muta-
ions was 9.83 nM for RAL (range 8.23–13.53 nM), compared with
.31 nM for EVG (range 4.00–9.55 nM), and only 1.97 nM for DTG
range 1.67–2.14 nM). Their calculated mean fold changes (FC) for
AL ranged from 1.38 to 2.12, for EVG from 0.64 to 1.52, and for
TG from 0.92–1.18.
The IC50 values and FCs of clone #6, harbouring only the minor
AL resistance mutation V151I, were comparable to the wild-type
alues for all INIs with a mean FCs of 1.97 for RAL (range 1.20–2.86),
.95 for EVG (range 0.92–0.98) and 1.31 for DTG (range 1.23–1.35)
Table 3).
The clones harbouring RAL resistance mutations, #7, #8, and #9,
evealed higher IC50 and FC values for RAL and EVG compared to
he wildtype strains, as expected (Table 3; Fig. 4). Regarding DTG,
he RAL-resistant clones #7 and #8 presented no reduction in sus-
eptibility (mean FCs of 1.3 and 0.6, respectively). Overall, clone #9
Q148H + G140S) presented the highest resistance against RAL andEVG (FC > 200), and also reduced sensitivity to DTG (mean FC 3.44;
range 3.13–3.73).
For the determination of the IC50 values and the calculation of
the FC values, the phenotypic analyses were performed in tripli-
cate, independently (see standard deviation). For proving our data,
the calculated FC values were compared to predicted FC values
obtained with geno2pheno[integrase] (Table 3). There is a strong pos-
itive correlation between measured and predicted FC values. The
Pearson’s correlation coefﬁcients (R) were 0.98 for RAL and 1.00 for
EVG. As this phenotype-based interpretation tool only offers pre-
dictions for RAL and EVG, virtual determination of FC values for DTG
was not possible.4. Discussion
HIV integrase inhibitors are potent antiretroviral drugs that efﬁ-
ciently decrease viral load in HIV-1 infected patients. Since 2007,
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Fig. 3. Relative SEAP activity of the HIV-1 clones #1-5 without described RAL-associated mutations in the presence of the integrase inhibitors RAL, EVG and DTG.
Relative SEAP (Secreted Placental Alkaline Phosphatase-gene) activity of the HIV-1 subtype B clones #1-5 in the presence of increasing concentrations of A: raltegravir (RAL),
B:  elvitegravir (EVG) and C: dolutegravir (DTG).
Fig. 4. Relative SEAP activity of the HIV-1 clones #6-9 harbouring described RAL-associated mutations in the presence of the integrase inhibitors RAL, EVG and DTG.
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the INI RAL is a successful component of antiretroviral therapies.
However, single mutations in the integrase are sufﬁcient to confer
high-level resistance (reviewed in (Metiﬁot et al., 2010)), charac-
terizing RAL as a drug with a low genetic barrier to resistance. This
characteristic led to a large increase of INI-resistant viruses in HIV-
1 infected patients, due to the emergence of INI-resistant viruses
upon therapy failure, but also due to the transmission of INI resis-
tant viruses (Boyd et al., 2011; Hurt, 2011; Young et al., 2011). With
the approval of the INIs EVG and DTG in the recent years, two  further
potent INIs are available. However, the sequential use of RAL and
EVG is not recommended, due to the high level of cross-resistance
to these compounds (Garrido et al., 2012). Thus, currently only
DTG can be used in a combination therapy after RAL or EVG have
failed, since DTG is characterized to be widely active against HIV-
1 variants isolated from RAL-treated patients (Underwood et al.,
2012).
We  devised a recombinant susceptibility assay, which facilitates
the investigation of the complete integrase gene region. This will
permit the analysis of genotypic and phenotypic resistance and
cross-resistance to the different INIs and the identiﬁcation of cur-
rently insufﬁciently characterized resistance proﬁles of the recent
INIs, available or under development.
After successful cloning and cultivation of recombinant virus
with representative mutations for RAL-naive and RAL-experienced
viruses, the different clones were analysed for their susceptibility
against RAL, EVG, and DTG. The virus strains without detected resis-
tance mutations demonstrated FCs predominantly comparable to
the wild-type reference strain NL4-3lig IN for RAL, EVG and DTG.
The viruses harbouring described RAL-resistance mutations pre-
sented reduced susceptibility to the different INIs according to their
mutation pattern. The primary RAL resistance mutation N155 and
Q148 resulted in high resistance to RAL and EVG, while the primary
RAL mutation Y143 just inﬂuenced the RAL susceptibility, proving
the low impact of the Y143R on EVG and DTG resistance (Metiﬁot
et al., 2011; Underwood et al., 2012). The determined FCs of the
analysed virus strains harbouring different RAL-speciﬁc mutation
patterns in our phenotypic susceptibility assay are comparable to
other in-vitro data (Canducci et al., 2011; Van Wesenbeeck et al.,
2011). Beside the Y143R mutation, DTG also maintained activity
to the isolate with the N155H mutations. Thus, the activity of DTG
was only reduced for the virus strain carrying the Q148H mutation
in combination with a secondary RAL-resistance mutation, as also
reported by other in vitro studies (Underwood et al., 2012).
The phenomenon of the determination of high IC50 values of
recombinant clones for speciﬁc drugs despite of genotypic fully sus-
ceptibility, as determined for the recombinant wildtype clone #2,
can most probably be attributed to a reduced replication capacity.
Generally, reduced replication capacity can be observed in resistant
variants but was also in susceptible isolates down to 65% compared
to the reference strain depending on the analysed drug (De Luca
et al., 2007; Walter et al., 2002). Replication reduced virus variants
need higher amounts of input virus and show unexpected high IC50
values in our assay system. The virus titration assay calculates the
virus input inducing 20.000 RLUs 3 days after infection. As repli-
cation competent viruses ﬁnalize at least two  replication cycles
in 3 days, replication reduced variants achieve less. Due to the
reduced replication capacity a higher amount of virus supernatant
is required to gain a reporter gene expression comparable to the
reference strain. It contains more infectious virus particles and also
more natural secreted tat protein, the inducer of the SEAP reporter
gene, which lead to an incomplete inhibition of the virus replication
(Xiao et al., 2000). The variation of the IC50 values between the dif-
ferent antiretroviral drugs is drug dependent (De Luca et al., 2007).
These data illustrate the limitations of phenotypic susceptibility
testing by the use of recombinant viruses, as other regions outside
the integrase gene region play a role in determining viral ﬁtness.
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here is a signiﬁcant inﬂuence of pol fragments on the replica-
ion capacity of HIV-1; the conditions for the phenotypic resistance
nalysis of chimeric viruses are complex (Brumme  et al., 2011;
ordanskiy et al., 2010). This limitation was also observed during our
rst attempt to generate chimeric viruses of non-B integrase genes
n the pNL4-3 subtype-B backbone, as these recombinants were
ot able to generate a sufﬁcient number of recombinant particles
s required by the susceptibility assay.
Overall, the determined IC50 values of the wild type strains were
-fold and 3.2-fold higher for RAL and EVG compared to DTG, con-
rming the low DTG drug concentrations needed for the inhibition
f viral replication (Seki et al., 2015). The intrinsic variability of our
henotypic IN susceptibility assay is comparable to the reverse-
ranscriptase and protease inhibitor assay described by Walter et al.
Walter et al., 1999).
Mean FC values for RAL and EVG measured by our phenotypic
usceptibility assay are strongly positively correlated to FC values
redicted by geno2pheno[integrase]. Similar results were observed
or a phenotypic drug susceptibility assay for HIV protease and
everse transcriptase which was compared to predicted values pro-
uced with a genotype-based phenotyping algorithm (Pattery et al.,
012; Van Houtte et al., 2009).
Phenotypic resistance testing is time consuming and fails to pro-
uce (accurate) results in a variety of settings, e.g. low viral load of
he plasma samples and reduced ﬁtness of the generated recombi-
ants. However, it is an invaluable tool for resistance determination
n patients who harbour viruses with complex genetic patterns or
or drugs with insufﬁciently characterized mutational resistance
roﬁles.
In order to improve the INI-resistance predictions by
eno2pheno[integrase], more genotype-phenotype pairs are
equired. In this context, it is especially important that inde-
endent data describing phenotypic resistance after therapy
ailure in routine clinical practice be generated. Furthermore, the
eneration of resistance data for DTG and other, investigational
NIs will allow geno2pheno[integrase] to offer predictions for these
rugs. Last but not least, the generation of a sufﬁcient amount
f phenotypic resistance data for INIs will allow for the robust
etermination of clinically-relevant cutoffs for the fold-change in
rug resistance.
In conclusion, the established phenotypic INI resistance assay
ermits resistance analysis of the complete IN gene of patient-
erived viruses for INIs. Thus, the assay can be used for the
nalysis of newly appearing mutational resistance patterns of
ecent INIs providing resistance data for interpretation system
eno2pheno[integrase] in future.
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